HONG KONG – South Korean AI-based biotech Azoth Bio Inc., of Seongnam, Gyeonggi-do, and biopharmaceutical venture Wellmarker Bio Co. Ltd., based in Seoul, have signed a memorandum of understanding for cancer drug R&D and commercialization. Under the agreement, the two entities will use Azoth's AI-powered platform to develop Wellmarker's cancer treatment candidates.

RNAi specialist Dicerna Pharmaceuticals Inc.'s chief operating officer, James Weissman, told BioWorld that scientists inside and outside of the company have come to believe in what's called "the X hypothesis" in hepatitis B virus (HBV). "My view, though, as a person who has been in the pharmaceutical industry for decades, is who cares, anyway?" he said – as long as the drug works. He pointed out that, with the cholesterol therapy Lipitor (atorvastatin calcium) from New York-based Pfizer Inc., where he served in business development and marketing, "everybody had a different theory for why it lowered the incidence of heart disease. Nobody knew with certainty."

Pandion Therapeutics Inc.'s deal with Astellas Pharma Inc. brings as much as $45 million in up-front money and payments related to research and preclinical activities, with potentially more than $750 million in development and commercial milestone rewards to come, plus royalties if products reach the market.

HONG KONG – South Korean biotech company Qurient Co. Ltd. has inked a joint venture (JV) foundation deal involving Germany's Max Planck Society (MPG), of Munich, and Lead Discovery Center GmbH (LDC) in Dortmund, as well as the 1988 Nobel laureate and biochemist Robert Huber.

HONG KONG – One of South Korea's biggest pharmaceutical companies by market capitalization, GC Pharma Corp., based in Yong-in, Gyeonggi-do, and the Cambridge, Mass.-based U.S. biotech Vaxess Technologies Inc., have partnered to globally commercialize a flu vaccine patch based on Vaxess' Mimix Smart Release Patch technology.

BEIJING – Sino-U.S. infectious diseases specialist Brii Biosciences Inc., with U.S. offices in Durham, N.C., and San Francisco, and China offices in Beijing and Shanghai, is bringing to greater China three investigational products from anti-infective therapy developer Qpex Biopharma Inc., of San Diego, to treat various multidrug-resistant gram-negative infections.

BOGOTA, Colombia – Looking to dig deeper into its rest-of-the-world market operations, Canadian firm Knight Therapeutics Inc. acquired Latin America's largest biotech company, Biotoscana Investments SA.

HONG KONG – South Korean biotech company Qurient Co. Ltd. has inked a joint venture (JV) foundation deal involving German companies Max Planck Society (MPG), of Munich, and Lead Discovery Center GmbH (LDC) in Dortmund, as well as the 1988 Nobel laureate and biochemist Robert Huber.

HONG KONG – South Korea's major pharmaceutical company GC Pharma Corp., based in Yong-in, Gyeonggi-do, and the Cambridge, Mass.-based U.S. biotech Vaxess Technologies Inc., have partnered to globally commercialize a flu vaccine patch based on Vaxess' Mimix Smart Release Patch technology. The patch is designed to deliver medicines and vaccines through silk microneedles that dissolve at a precise rate.

HONG KONG – South Korea's major pharmaceutical company GC Pharma Corp., based in Yong-in, Gyeonggi-do, and the Cambridge, Mass.-based U.S. biotech Vaxess Technologies Inc., have partnered to globally commercialize a flu vaccine patch based on Vaxess' Mimix Smart Release Patch technology. The patch is designed to deliver medicines and vaccines through silk microneedles that dissolve at a precise rate.